Skip to content
Guess what? Valuesider just got better: smarter and more intuitive.
Elevance Health Inc

ELV

Elevance Health Inc

Elevance Health Inc historical holders

total: 16

Brave Warrior Advisors Elevance Health Inc transactions over time

Total transactions:
27
New positions:
1
Added:
10
Reduced:
16
Held since:
2019 Q3
Held for:
27 quarters
Latest activity:
2026 Q1
Glenn Greenberg has been an institutional investor in Elevance Health Inc (ELV) since 2019 Q3. According to 2026 Q1 report, Glenn Greenberg holds 1,122,308 shares with a market value of roughly $328.56M representing 8.13% of their equity portfolio. The fund/company first acquired ELV in 2019 Q3, initially purchasing 638,397 shares. Since the initial investment, Brave Warrior Advisors has made 26 more transactions in this position.

Does Glenn Greenberg still hold ELV?

Yes, Glenn Greenberg continues to hold Elevance Health Inc (ELV). According to their 2026 Q1 report, they maintain a position of 1,122,308 shares valued at approximately $328.56M, representing 8.13% of their equity portfolio.

When did Glenn Greenberg first invest in ELV?

Glenn Greenberg first invested in Elevance Health Inc (ELV) in 2019 Q3 at the reported quarter-end price of $240.10 per share, acquiring 638,397 shares in their initial purchase.

What is Glenn Greenberg's average cost basis for ELV?

Based on historical transaction data, Glenn Greenberg's estimated cost basis for Elevance Health Inc (ELV) is approximately $342.72 per share. This represents their average reported price* across all buy transactions.

Estimated cost basis*

Weighted AVG buy price:
$342.72
Weighted AVG sell price:
$401.09

ELV transactions history by Brave Warrior Advisors

27 results
Period % of
portfolio
Shares
held after*
Reported
price*
Value* % (shares)
of activity
% change
to portfolio
2026 Q1
8.13%
1,122,308
$292.75
$328,555,667
-10.34% (-129,495)
-0.89%
2025 Q4
10.28%
1,251,803
$350.55
$438,819,542
-31.74% (-582,199)
-4.74%
2025 Q3
13.76%
1,834,002
$323.12
$592,602,726
+65.28% (+724,349)
+5.43%
2025 Q2
9.89%
1,109,653
$388.96
$431,610,631
-29.66% (-467,917)
-4.17%
2025 Q1
15.72%
1,577,570
$434.96
$686,179,847
-3.22% (-52,407)
-0.57%
2024 Q4
14.96%
1,629,977
$368.90
$601,298,515
-0.70% (-11,436)
-0.09%
2024 Q3
17.71%
1,641,413
$520.00
$853,534,760
+0.51% (+8,286)
+0.09%
2024 Q2
19.61%
1,633,127
$541.86
$884,926,196
-0.77% (-12,710)
-0.14%
2024 Q1
17.85%
1,645,837
$518.54
$853,432,318
-6.31% (-110,816)
-1.37%
2023 Q4
19.76%
1,756,653
$471.56
$828,367,289
+7.93% (+129,055)
+1.45%
2023 Q3
17.69%
$435.42
+23.18% (+306,326)
2023 Q2
15.51%
$444.29
+21.80% (+236,504)
2023 Q1
15.43%
$459.81
+24.34% (+212,353)
2022 Q4
14.10%
$512.97
-26.68% (-317,456)
2022 Q3
18.68%
$454.24
-1.77% (-21,405)
2022 Q2
20.07%
$482.58
-10.49% (-141,973)
2022 Q1
19.61%
$491.22
-0.92% (-12,536)
2021 Q4
20.17%
$463.54
-0.40% (-5,477)
2021 Q3
17.90%
$372.80
+19.72% (+225,846)
2021 Q2
15.01%
$381.80
-1.57% (-18,313)
2021 Q1
13.64%
$358.95
+50.91% (+392,594)
2020 Q4
9.11%
$321.09
+0.94% (+7,208)
2020 Q3
9.16%
$268.59
-0.98% (-7,541)
2020 Q2
10.09%
$262.98
-11.88% (-103,999)
2020 Q1
11.44%
$227.04
+39.48% (+247,815)
2019 Q4
10.02%
$302.03
-1.68% (-10,745)
2019 Q3
8.18%
$240.10
new
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.